Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is one of the largest biopharmaceutical companies globally, headquartered in North Chicago, Illinois. The company specializes in immunology, oncology, neuroscience, aesthetics, and eye care therapeutics, making its news coverage particularly valuable for tracking developments across multiple billion-dollar healthcare markets.
AbbVie news reflects the company diverse therapeutic focus. Immunology updates often include clinical trial results for next-generation autoimmune disease treatments, including JAK inhibitors and other novel mechanisms targeting conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. These announcements can signal shifts in competitive dynamics within the autoimmune drug market.
The oncology division generates news around FDA approvals, clinical trial data, and pipeline developments for cancer therapies. AbbVie cancer portfolio includes treatments for hematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma, with ongoing expansion into solid tumor indications. Drug approval timelines and efficacy data from late-stage trials represent key news catalysts.
Neuroscience news covers developments in migraine treatment and Parkinson disease therapies, including CGRP-targeting drugs and advanced delivery systems. The Allergan Aesthetics division, acquired through AbbVie purchase of Allergan, generates news around cosmetic treatment innovations, market expansion, and competitive positioning in the medical aesthetics space.
Quarterly earnings reports provide insight into segment performance across immunology, oncology, and aesthetics divisions. Strategic announcements regarding acquisitions, licensing deals, and pipeline partnerships appear regularly as AbbVie pursues external innovation to supplement internal research. Bookmark this page to track regulatory decisions, clinical milestones, and strategic moves from one of biopharma largest players.
AbbVie’s Allergan Aesthetics and skinbetter science launched the Forces of Beauty report on Sept. 22, 2022, under the DREAM Initiative. The report explores racial representation in beauty standards, revealing that only 17% of women feel their racial beauty is accepted. Key findings show 1 in 4 women of color perceive beauty standards as racist. In tandem, a new royalty-free image gallery, resulting from a partnership with Shutterstock Studios, aims to promote diverse representations across various demographics. The initiative seeks to foster dialogue and education around inclusive beauty.
AbbVie (NYSE: ABBV) received a positive opinion from the EMA's CHMP for risankizumab (SKYRIZI®) to treat adults with moderately to severely active Crohn's disease. The recommendation stems from three Phase 3 studies showing significant improvements in clinical remission and endoscopic response at 12 weeks post-treatment. If approved, this would be the first specific IL-23 inhibitor available for Crohn's disease in the EU. A final European Commission decision is expected in Q4 2022, marking the third indication for risankizumab in the region.
AbbVie announced it will present findings from the Phase 3 M15-736 trial and data on BOTOX at the 2022 MDS International Congress in Madrid from September 15-18. Key presentations include results on the continuous infusion of ABBV-951 for advanced Parkinson's disease and real-world efficacy of BOTOX for spasticity and cervical dystonia. AbbVie emphasizes its commitment to addressing the needs of patients with movement disorders, reinforcing its leadership in neuroscience.
AbbVie has opened public voting for its 30th annual Cystic Fibrosis (CF) Scholarship program, running until September 28. This year, 40 students living with CF are competing for two $25,000 scholarships based on academic excellence and community involvement. Earlier in 2022, AbbVie awarded $3,000 to 40 CF students, totaling over $3.7 million in scholarships since the program's inception. The winners will be announced in early November, highlighting AbbVie's commitment to supporting the CF community.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the selection of 25 real patients for its new BOTOX® Cosmetic 'See Yourself' campaign after receiving nearly 20,000 submissions. The campaign aims to showcase authentic testimonials and experiences, reflecting the emotional and physical impact of BOTOX® treatments. The latest content includes interviews, treatment diaries, and informative sessions addressing common patient inquiries. BOTOX® Cosmetic remains the leading product in its category, approved by the FDA for treating facial lines.
AbbVie announced 100-week results from KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI (risankizumab) in adults with active psoriatic arthritis. Over 50% of patients achieved a 90% reduction in psoriasis severity (PASI 90), with similar joint symptom improvement (ACR20) as at week 52. The treatment maintained long-term efficacy, with no new safety signals observed. Serious treatment-emergent adverse events were low, with a rate of 7.6 E/100PY in KEEPsAKE 1. These findings were presented at the 31st EADV Congress, highlighting SKYRIZI's potential as a long-term treatment option.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on November 15, 2022, to shareholders of record by October 14, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250%. The company is a member of the S&P Dividend Aristocrats Index, which includes firms that have consistently raised dividends for at least 25 consecutive years.
AbbVie's MEASURE-AD study, spanning three years and 28 countries, highlights the significant clinical, psychosocial, and economic burdens faced by patients with moderate to severe atopic dermatitis, particularly those not on systemic therapy. Results presented at the EADV Congress indicate that these patients experience higher disease severity scores and lower quality of life, emphasizing the need for improved treatment options. The analysis shows that only half of eligible patients receive systemic therapy, revealing potential undertreatment in this population.
AbbVie announced new data from its migraine portfolio at the Migraine Trust International Symposium 2022 in London, from September 8-11. The presentation will include results from the Phase 3 PROGRESS trial for atogepant, aimed at preventing chronic migraine, alongside additional studies on onabotulinumtoxinA and ubrogepant. The company will highlight its commitment to addressing the unmet needs of migraine patients. A medical symposium titled "Evolving Faces of Migraine" will also take place during the event.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
